Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18595656 | METHODS OF TREATING OR PREVENTING STENT THROMBOSIS | March 2024 | May 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18413260 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL ANTIDIABETIC DRUG | January 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18407324 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | January 2024 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18354372 | PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS | July 2023 | August 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18323208 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | May 2023 | March 2025 | Abandon | 22 | 1 | 0 | No | No |
| 17810513 | PEPTIDES AND METHODS FOR TREATING DISEASE | July 2022 | October 2024 | Allow | 27 | 3 | 0 | No | Yes |
| 17713809 | CYCLIN G1 INHIBITORS AND RELATED METHODS OF TREATING CANCER | April 2022 | August 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17698353 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | March 2022 | December 2025 | Allow | 45 | 2 | 1 | No | No |
| 17641779 | METHODS OF TREATMENT RELATED TO COMPLEXES OF VON WILLEBRAND FACTOR AND COMPLEMENT C1Q | March 2022 | June 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17636839 | UBE3A FOR THE TREATMENT OF ANGELMAN SYNDROME | February 2022 | October 2025 | Allow | 44 | 1 | 2 | Yes | No |
| 17631121 | SS-31 FOR THE PREVENTION AND/OR TREATMENT OF ANEURYSM | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17626675 | FUSION TOXIN PROTEINS FOR TREATMENT OF DISEASES RELATED TO CMV INFECTIONS | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17609784 | Ras INHIBITORY PEPTIDE | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17603080 | AMANTADINE BINDING PROTEIN | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17409692 | METHOD FOR PRODUCING PEPTIDE COMPOUND, PROTECTIVE GROUP-FORMING REAGENT, AND AROMATIC HETEROCYCLIC COMPOUND | August 2021 | December 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17420622 | METHODS OF PROMOTING REMYELINATION | July 2021 | November 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17314550 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | May 2021 | April 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17277468 | MODIFIED CHANNEL RHODOPSIN | March 2021 | December 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17100376 | Shape Memory Silk Materials | November 2020 | January 2025 | Abandon | 50 | 2 | 0 | No | Yes |
| 16866764 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | May 2020 | May 2024 | Allow | 49 | 5 | 0 | Yes | No |
| 16010902 | PREPARATION OF TEMPLATES FOR NUCLEIC ACID SEQUENCING | June 2018 | November 2019 | Allow | 17 | 1 | 1 | No | No |
| 15472555 | ARRAYS OF MICROPARTICLES AND METHODS OF PREPARATION THEREOF | March 2017 | March 2018 | Allow | 11 | 0 | 0 | No | No |
| 15389802 | Modified Apidaecin Derivatives as Antibiotic Peptides | December 2016 | May 2019 | Allow | 29 | 2 | 1 | Yes | No |
| 15321561 | METHODS AND COMPOSITIONS FOR INHIBITING GROWTH AND EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) IN CANCER CELLS | December 2016 | July 2019 | Allow | 31 | 2 | 1 | Yes | No |
| 15306266 | AGENTS AND METHODS FOR TREATMENT OF PATHOGENS | October 2016 | October 2018 | Allow | 24 | 1 | 1 | Yes | No |
| 15258786 | METHOD OF AMELIORATING OR PREVENTING THE WORSENING OR THE PROGRESSION OF SYMPTOMS OF BPH | September 2016 | August 2019 | Allow | 36 | 4 | 1 | No | No |
| 15217326 | NOVEL JNK INHIBITOR MOLECULES FOR TREATMENT OF VARIOUS DISEASES | July 2016 | August 2019 | Allow | 37 | 3 | 0 | Yes | No |
| 14943752 | Compositions and Methods for Preventing or Treating Diseases, Conditions, or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix Deposition | November 2015 | July 2019 | Allow | 44 | 4 | 1 | Yes | No |
| 13984715 | HYDROPHOBIC MODIFIED PEPTIDES FOR LIVER SPECIFIC DIAGNOSIS | August 2014 | March 2019 | Allow | 60 | 5 | 1 | Yes | No |
| 14122956 | METHOD OF TREATING DISORDERS USING A PHARMACEUTICAL COMPOSITION OF OLIGOPEPTIDES | January 2014 | November 2018 | Allow | 60 | 3 | 1 | Yes | No |
| 13555595 | NANOPARTICULATE CELL CULTURE SURFACE | July 2012 | March 2013 | Allow | 8 | 1 | 0 | No | No |
| 13309734 | Peptides and peptide compositions having osteoinductive activity | December 2011 | May 2014 | Allow | 30 | 1 | 1 | Yes | No |
| 12949104 | METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR | November 2010 | May 2014 | Allow | 42 | 3 | 1 | Yes | No |
| 12910468 | Arrays of microparticles and methods of preparation thereof | October 2010 | May 2012 | Abandon | 19 | 1 | 1 | Yes | No |
| 12746996 | Polypeptides, Cyclic Polypeptides and Pharmaceutical Comprising Thereof for Non Invasive Specific Imaging of Fibrosis | August 2010 | February 2013 | Allow | 32 | 1 | 0 | Yes | No |
| 12810470 | TOPICAL COMPOSITIONS FOR DELIVERY OF PROTEINS AND PEPTIDES | June 2010 | November 2012 | Abandon | 28 | 0 | 1 | No | No |
| 12747435 | CROSS-LINKED HYDROGEL CONTAINING AN ACTIVE SUBSTANCE | June 2010 | January 2013 | Abandon | 31 | 0 | 1 | No | No |
| 12747013 | ASSAY SYSTEM AND METHOD | June 2010 | September 2012 | Allow | 27 | 1 | 1 | No | No |
| 12786287 | APPARATUS FOR POLYMER SYNTHESIS | May 2010 | February 2013 | Abandon | 33 | 2 | 1 | No | No |
| 12744390 | FLEXIBLE EXTRACTION METHOD FOR THE PRODUCTION OF SEQUENCE-SPECIFIC MOLECULE LIBRARIES | May 2010 | March 2012 | Abandon | 21 | 0 | 1 | No | No |
| 12440832 | Methods and Devices for Detecting Structural Changes in a Molecule Measuring Electrochemical Impedance | April 2010 | October 2012 | Abandon | 43 | 2 | 1 | No | No |
| 12757499 | HIGH THROUGHPUT SCREENING OF ION CHANNELS | April 2010 | October 2012 | Allow | 30 | 2 | 1 | Yes | No |
| 12730043 | Treatment of Cancers with Immunostimulatory HIV TAT Derivative Polypeptides | March 2010 | May 2013 | Allow | 38 | 1 | 1 | Yes | No |
| 12683662 | DOSING FORMS AND REGIMENS COMPRISING 3-[(R)-2-(N,N-DIMETHYLAMINO)ETHYLTHIO-SAR]-4-(GAMMAHYDROXYMETHYLLEUCINE)CYCLOSPORINE | January 2010 | March 2013 | Abandon | 38 | 1 | 1 | No | No |
| 12683841 | COMPOSITIONS FOR ENHANCING NAIL GROWTH | January 2010 | February 2013 | Abandon | 37 | 1 | 1 | No | No |
| 12664510 | APOA-1 PEPTIDE MIMETICS | December 2009 | February 2013 | Abandon | 38 | 0 | 1 | No | No |
| 11989901 | ASSAYS FOR S100 INHIBITORS | December 2009 | May 2012 | Allow | 52 | 3 | 1 | Yes | No |
| 12629068 | HAIR-BINDING PEPTIDES | December 2009 | November 2012 | Abandon | 36 | 0 | 1 | Yes | No |
| 12626277 | NANOPARTICULATE CELL CULTURE SURFACE | November 2009 | October 2012 | Allow | 34 | 1 | 1 | No | No |
| 12528926 | TEMPLATE-FIXED PEPTIDOMIMETICS | October 2009 | November 2012 | Allow | 38 | 1 | 0 | No | No |
| 12596600 | IMMOBILIZED PROTEIN THAT IS IMMOBILIZED ONLY AT ITS AMINO TERMINUS IN ORIENTATION-CONTROLLED MANNER | October 2009 | November 2012 | Abandon | 37 | 1 | 1 | No | No |
| 12310279 | LYSINE ACETYLATION SITES | September 2009 | September 2012 | Abandon | 43 | 0 | 1 | No | No |
| 12547658 | Method for Decreasing Interference in Results of Immunochemical Methods | August 2009 | March 2012 | Abandon | 30 | 2 | 0 | Yes | No |
| 12547294 | ORAL MEDICATION FOR THE TREATMENT OF HEMORRHOIDS AND METHOD OF USE | August 2009 | September 2012 | Abandon | 36 | 1 | 1 | No | No |
| 12503260 | DETECHIP: MOLECULAR COLOR AND FLUORESCENT SENSORY ARRAYS FOR SMALL MOLECULES | July 2009 | August 2012 | Abandon | 37 | 0 | 1 | No | No |
| 12477186 | Methods, systems, and kits for identification of osteoinductive peptides | June 2009 | February 2013 | Abandon | 45 | 2 | 1 | No | No |
| 12085785 | Identification of Genetic Polymorphic Variants Associated With Somatosensory Disorders and Methods of Using the Same | June 2009 | January 2013 | Abandon | 55 | 2 | 1 | Yes | No |
| 12446682 | METHOD FOR PROFILING KINASE INHIBITORS | April 2009 | December 2012 | Abandon | 44 | 2 | 1 | No | No |
| 12423728 | QUANTITATIVE MICROARRAY OF INTACT GLYCOLIPID CD1D INTERACTION AND CORRELATION WITH CELL-BASED CYTOKINE PRODUCTION | April 2009 | October 2012 | Allow | 42 | 2 | 1 | Yes | Yes |
| 12443623 | PROTEIN APPROPRIATE FOR ORIENTATION-CONTROLLED IMMOBILIZATION AND IMMOBILIZATION CARRIER ON WHICH THE PROTEINS ARE IMMOBILIZED | March 2009 | October 2012 | Abandon | 43 | 2 | 2 | No | No |
| 12441520 | BIOMOLECULE DETECTION REAGENT AND METHOD FOR DETECTING BIOMOLECULE USING THE SAME | March 2009 | August 2012 | Abandon | 41 | 3 | 0 | No | No |
| 12351465 | FUNCTIONAL PROTEIN ARRAYS | January 2009 | March 2012 | Abandon | 38 | 0 | 1 | No | No |
| 12159977 | USE OF POLYMERS FOR INCREASING THE SIGNAL INTENSITY WHEN CARRYING OUT DETECTION REACTIONS | December 2008 | June 2012 | Abandon | 47 | 2 | 1 | Yes | No |
| 11989169 | Preparation of templates for nucleic acid sequencing | December 2008 | May 2012 | Abandon | 52 | 1 | 1 | No | No |
| 12329527 | METHODS AND DEVICES FOR ENHANCED BIOCOMPATIBILITY | December 2008 | March 2012 | Abandon | 40 | 0 | 1 | No | No |
| 12325462 | MULTI-MODE MICROARRAY APPARATUS AND METHOD FOR CONCURRENT AND SEQUENTIAL BIOLOGICAL ASSAYS | December 2008 | June 2012 | Abandon | 42 | 1 | 1 | No | No |
| 12264241 | DNA MICRO-ARRAY HAVING STANDARD PROBE AND KIT INCLUDING THE ARRAY | November 2008 | August 2012 | Abandon | 45 | 2 | 0 | No | No |
| 12258139 | METHOD OF PREPARING A SUBSTRATE WITH A COMPOSITION INCLUDING AN ORGANOBORANE INITIATOR | October 2008 | October 2012 | Allow | 48 | 1 | 1 | Yes | No |
| 10585373 | Modified Molecular Arrays | October 2008 | October 2012 | Abandon | 60 | 2 | 1 | No | No |
| 11989838 | Gene involved in occurrence/recurrence of hcv-positive hepatocelluar carcinoma | August 2008 | August 2012 | Abandon | 54 | 2 | 2 | No | No |
| 12221750 | Isolation of nucleic acids molecules using modified solid supports | August 2008 | February 2012 | Abandon | 42 | 0 | 1 | No | No |
| 12153911 | Method for biomolecule immobilization | May 2008 | December 2012 | Abandon | 55 | 3 | 1 | No | No |
| 11947724 | LOCKED NUCLEIC ACID REAGENTS FOR LABELLING NUCLEIC ACIDS | November 2007 | June 2012 | Allow | 60 | 3 | 1 | Yes | No |
| 11262300 | DNA-templated combinatorial library device and method for use | October 2005 | June 2012 | Abandon | 60 | 3 | 2 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GARYU, LIANKO G.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner GARYU, LIANKO G works in Art Unit 1654 and has examined 62 patent applications in our dataset. With an allowance rate of 41.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner GARYU, LIANKO G's allowance rate of 41.9% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GARYU, LIANKO G receive 1.60 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GARYU, LIANKO G is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +57.1% benefit to allowance rate for applications examined by GARYU, LIANKO G. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 29.4% of applications are subsequently allowed. This success rate is in the 56% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 60.0% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 83.3% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.7% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.